Law firm analysis says prescribing architecture is next compounding question after Empower
The commentary argues telehealth and compounding operators running at scale now face scrutiny of how prescriptions are generated, not just what is compounded.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 15 16:35 ETSource: JD Supra
The wire
- 01A JD Supra legal analysis frames post-Empower compounding and telehealth oversight around prescribing architecture, the structures through which patient prescriptions are issued at scale.
- 02Telehealth operators and 503A/503B partners are the audience, since the argument shifts regulatory risk toward intake, clinician review and prescription-generation design.
- 03The piece is law-firm commentary rather than agency action, and the underlying regulatory positions it describes remain subject to change.
From the source
Read at jdsupra.comCompounding and Telehealth at Scale After Empower: Prescribing Architecture Is the New Regulatory Question
